GC
CTIC

Guggenheim Capital’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Guggenheim Capital’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-16,349
Closed -$64K – 2797
2018
Q1 		$64K Buy
16,349
+4,499
+38% +$15.8K ﹤0.01% 2693
2017
Q4 		$32K Sell
11,850
-1,480
-11% -$4.34K ﹤0.01% 2655
2017
Q3 		$43K Buy
+13,330
New +$44.5K ﹤0.01% 2710
2017
Q1 		– Sell
-6,302
Closed -$25K – 3008
2016
Q4 		$25K Hold
6,302
– – ﹤0.01% 2835
2016
Q3 		$24K Sell
6,302
-57
-0.9% -$208 ﹤0.01% 2813
2016
Q2 		$22K Sell
6,359
-456
-7% -$2.09K ﹤0.01% 2806
2016
Q1 		$36K Buy
6,815
+2,045
+43% +$16.3K ﹤0.01% 2802
2015
Q4 		$59K Buy
4,770
+734
+18% +$9.8K ﹤0.01% 2886
2015
Q3 		$59K Sell
4,036
-192
-5% -$3.32K ﹤0.01% 2841
2015
Q2 		$83K Buy
4,228
+178
+4% +$3.44K ﹤0.01% 2917
2015
Q1 		$73K Buy
4,050
+838
+26% +$18.9K ﹤0.01% 2894
2014
Q4 		$76K Buy
3,212
+474
+17% +$11K ﹤0.01% 2876
2014
Q3 		$67K Sell
2,738
-4,081
-60% -$106K ﹤0.01% 2911
2014
Q2 		$192K Sell
6,819
-986
-13% -$29.6K ﹤0.01% 2915
2014
Q1 		$266K Buy
7,805
+1,334
+21% +$45.6K ﹤0.01% 2784
2013
Q4 		$124K Buy
6,471
+254
+4% +$4.62K ﹤0.01% 2944
2013
Q3 		$102K Buy
6,217
+814
+15% +$9.43K ﹤0.01% 2852
2013
Q2 		$57K Buy
+5,403
New +$63.3K ﹤0.01% 2896

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Guggenheim Capital's CTIC Position: Q2 2018 in Review

Guggenheim Capital sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2018, closing a stake of 16,349 shares — an estimated $64K sold.

Guggenheim Capital first reported a position in CTIC in Q2 2013 and held it in 18 quarters. The position peaked at $266K in Q1 2014. 83 funds tracked by Wall St. Rank hold CTIC as of Q2 2018.

  • Guggenheim Capital reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2018 after selling out during the quarter.
  • Guggenheim Capital sold 16,349 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2018, an estimated $64K.
  • Guggenheim Capital first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 18 quarters.
  • Guggenheim Capital's CTI BioPharma Corp. (DE) Common Stock position peaked at $266K in Q1 2014.
  • 83 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2018.

Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.